University Hospitals Birmingham NHS Foundation Trust

Chapters

Status Drug name NICE TAs Comments
Status: Amber Amisulpride solution

Consultant initiation only, ESCA
Status: Amber Amisulpride tablets

Consultant initiation only, ESCA
Status: Amber Aripiprazole tablets

Supported by ESCA. The GP should be given a rationale for prescribing rather than first line antipsychotics. Approved for use in Tourette's Syndrome.
Status: Amber Chlorpromazine injection

ESCA
Status: Amber Chlorpromazine syrup

ESCA
Status: Amber Chlorpromazine tablets

ESCA
Status: Red Clozapine tablets

Only for emergency use in existing patients when inpatient at UHB
Status: Red Flupentixol decanoate injection

Hospital only. APC verdict - present status red. Future status amber with a framework in primary care before transfer (commissioning discussion).
Status: Amber Flupentixol tablets
Status: Red Fluphenazine decanoate injection

Hospital only. APC verdict - present status red. Future status amber with a framework in primary care before transfer (commissioning discussion).
Status: Amber Haloperidol capsules

ESCA
Status: Amber Haloperidol decanoate injection

Specialist initiation only
Status: Amber Haloperidol injection
Status: Amber Haloperidol SF liquid

ESCA
Status: Amber Haloperidol tablets
Status: Green Hyoscine patch

Very high relative cost
Status: Green Hyoscine tablets

Specialist initiation only
Status: Amber Levomepromazine injection

Consultant initiation only
Status: Amber Levomepromazine tablets (Nozinan®)

Consultant initiation only, ESCA
Status: Amber Lithium carbonate M/R tablet (Priadel)

Specialist initation only, ESCA
Status: Amber Lithium citrate liquid priadel

Specialist initiation only, ESCA
Status: Amber Olanzapine orodispersible tablets

Specialist initiation only, ESCA
Status: Amber Olanzapine tablets

Specialist initiation only, ESCA
Status: Red Paliperidone (Byannli®)

6 monthly injection
Status: Red Paliperidone (Trevicta®)
  • Third line option
  • Patient has been stable mentally for at least 12 months and had a stable dose of paliperidone palmitate monthly injection and has not required a dosage adjustment in the last six months
  • 12 months using the monthly injections and no dose adjustment for the last six months before considering the three-monthly injection
  • APC verdict - present status red. Future status amber with a framework in primary care before transfer (commissioning discussion)
Status: Red Paliperidone (Xeplion®)

APC verdict - present status = RED (Future status = AMBER with a framework in primary care before transfer - commissioning discussion) 
Status: Red Pirenzipine

Unlicensed
Status: Green Procyclidine SF syrup

Specialist initiation only
Status: Green Procyclidine tablets

Specialist initiation only
Status: Amber Quetiapine tablets

Specialist initiation only, ESCA
Status: Amber Quetiapine XL tablets

Supported by ESCA. The GP should be given a rationale for prescribing rather than first line antipsychotics. Brand rationalisation - APC preferred brads Biquelle XL, Sondate XL, Zaluron XL
Status: Red Risperidone injection

APC verdict - present status = RED (Future status = AMBER with a framework in primary care before transfer - commissioning discussion) 
Status: Amber Risperidone liquid

ESCA
Status: Amber Risperidone tablets

ESCA
Status: Amber Sulpiride tablets

ESCA
Status: Amber Trifluoperazine SF solution

Specialist initiation only, ESCA
Status: Amber Trifluoperazine tablets

Specialist initiation only, ESCA
Status: Amber Trihexyphenidyl

Specialist initiation only
Status: Amber Valproic acid as semisodium valproate tablets

Specialist initiation only
Status: Red Zuclopenthixol decanoate injection

APC verdict - present status = RED (Future status = AMBER with a framework in primary care before transfer - commissioning discussion)  
Status: Amber Zuclopenthixol tablets

Specialist initiation only, ESCA
Building healthier lives
Back to top